Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.66 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.63 |
| ▸ | HTR3B | O95264 | 1/20 | 0.63 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.63 |
| ▸ | HTR3A | P46098 | 1/20 | 0.63 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.63 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.63 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 3/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.59 |
| ▸ | GFER | P55789 | 1/20 | 0.59 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17144028 | 0.93 | F10 (0.64) | DRD2HTR3EHTR3BADRB1HTR3A | |
| SCHEMBL29656856 | 0.91 | HTR3E (0.73) | DRD2HTR3EHTR3BADRB1HTR3A | |
| SCHEMBL28599511 | 0.91 | HTR3E (0.73) | DRD2HTR3EHTR3BADRB1HTR3A | |
| SCHEMBL10498932 | 0.90 | HTR3E (0.62) | DRD2HTR3EHTR3BADRB1HTR3A | |
| SCHEMBL23657292 | 0.83 | ADRB1 (0.58) | DRD2ADRB1HTR3ARAB9ANPC1 | |
| SCHEMBL6153220 | 0.83 | ALDH1A1 (0.66) | DRD2HTR3EHTR3BADRB1HTR3A | |
| SCHEMBL14362730 | 0.83 | HTR3E (0.63) | DRD2HTR3EHTR3BADRB1HTR3A | |
| SCHEMBL28129519 | 0.83 | HTR3E (0.68) | DRD2HTR3EHTR3BADRB1HTR3A | |
| SCHEMBL2925759 | 0.83 | HTR3E (0.68) | DRD2HTR3EHTR3BADRB1HTR3A | |
| SCHEMBL15887431 | 0.82 | HTR3E (0.61) | DRD2HTR3EHTR3BADRB1HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0274259-B1 | New renin-inhibitory oligopeptides, their preparaton and their use | SANKYO CO (JP) | 1994-02-16 | — | — | EP | claimed |
| EP-0274259-A2 | New renin-inhibitory oligopeptides, their preparaton and their use | Sankyo Company Limited (JP) | 1988-07-13 | — | — | EP | claimed |
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | FUKANG (SHANGHAI) HEALTH TECHNOLOGY CO., LTD (CN) | 2024-01-18 | — | — | US | disclosed |
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | FUKANG (SHANGHAI) HEALTH TECHNOLOGY CO., LTD (CN) | 2024-01-18 | — | — | US | disclosed |
| CN-115448909-B | N-carbazolyl-1H-pyrrole-2-carboxamide and application thereof as ligand in copper-catalyzed C-N coupling reaction | 中山大学 | 2023-10-27 | — | — | CN | disclosed |
| US-20230015617-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| US-20220402891-A1 | TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2022-12-22 | — | — | US | disclosed |
| CN-115448909-A | N-carbazolyl-1H-pyrrole-2-formamide and application thereof as ligand in copper-catalyzed C-N coupling reaction | 中山大学 | 2022-12-09 | — | — | CN | disclosed |
| US-20220204497-A1 | NOVEL COMPOUND HAVING ANTICANCER ACTIVITY, AND METHOD FOR PRODUCING SAME | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2022-06-30 | — | — | US | disclosed |
| US-11160803-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2021-11-02 | — | — | US | disclosed |
| EP-3102204-B1 | HIGHLY SELECTIVE SIGMA 1 RECEPTOR LIGANDS AND RADIOLIGANDS AS PROBES IN NOCICEPTIVE PROCESSING AND THE PATHOPHYSIOLOGICAL STUDY OF MEMORY DEFICITS AND COGNITIVE DISORDERS | THE UNIV OF MISSISSIPPI (US) | 2021-05-05 | — | — | EP | disclosed |
| WO-2003020278-A1 | CYSTEINE PROTEASE INHIBITORS WITH 2-CYANO-4-AMINO-PYRIMIDINE STRUCTURE AND CATHEPSIN K INHIBITORY ACTIVITY FOR THE TREATMENT OF INFLAMMATIONS AND OTHER DISEASES | NOVARTIS AG (CH) | 2003-03-13 | — | — | WO | disclosed |
| EP-1097158-A2 | LIGANDS FOR METALS AND METAL-CATALYZED PROCESSES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2001-05-09 | — | — | EP | disclosed |
| US-6221868-B1 | Remedies/preventives for frequent urination/urinary incontinence and tropone derivatives | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2001-04-24 | — | — | US | disclosed |
| EP-0995741-A1 | REMEDIES/PREVENTIVES FOR FREQUENT URINATION/URINARY INCONTINENCE AND TROPONE DERIVATIVES | Nippon Kayaku Kabushiki Kaisha (JP) | 2000-04-26 | — | — | EP | disclosed |
| WO-2000002887-A2 | LIGANDS FOR METALS AND METAL-CATALYZED PROCESSES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2000-01-20 | — | — | WO | disclosed |
| US-5945421-A | TREATING PSYCHOSIS AND SCHIZOPHRENIA | WARNER-LAMBERT COMPANY (US) | 1999-08-31 | — | — | US | disclosed |
| US-5378690-A | Treatment of angiotensin induced hypertension | SANKYO COMPANY, LIMITED (JP) | 1995-01-03 | — | — | US | disclosed |
| EP-0274259-B1 | New renin-inhibitory oligopeptides, their preparaton and their use | SANKYO CO (JP) | 1994-02-16 | — | — | EP | disclosed |
| EP-0274259-A2 | New renin-inhibitory oligopeptides, their preparaton and their use | Sankyo Company Limited (JP) | 1988-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11160803-B2 | Phthalazinone derivatives | NR0B1, NR0B2, NR2E1 | DRD2 1019/4885HTR3E 1250/4885HTR3B 1135/4885 |
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | PARP3, PARP1, PARP4 | DRD2 4607/4885HTR3E 2681/4885HTR3B 2682/4885 |
| US-20220204497-A1 | NOVEL COMPOUND HAVING ANTICANCER ACTIVITY, AND METHOD FOR PRODUCING SAME | TPX2, AIMP2, CDYL2 | DRD2 2817/4885HTR3E 4677/4885HTR3B 4528/4885 |
| US-20230015617-A1 | PHTHALAZINONE DERIVATIVES | NR0B1, NR0B2, NR2E1 | DRD2 863/4885HTR3E 1238/4885HTR3B 1066/4885 |
| US-20220402891-A1 | TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | DRD2 3081/4885HTR3E 3609/4885HTR3B 4053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.